Adjuvant Immunotherapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Carlos RiverosEmily HuangSanjana RanganathanZachary KlaassenBrian RiniChristopher J D WallisRaj SatkunasivamPublished in: BJU international (2023)
The evidence base to date regarding ICI as adjuvant therapy in RCC is mixed - conclusions are limited by considerable heterogeneity between studies. However, pooled analyses suggest that patients with positive PD-L1 expression or sarcomatoid features are most likely to benefit from adjuvant immunotherapy.